Copertina

MAFLD in Egyptian non-dialysis CKD patients

Fuente: Zenodo

Salvato in:

Dettagli Bibliografici
Autore principale:	keryakos, hesham
Natura:	Recurso digital
Pubblicazione:	Zenodo 2025
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Rheocarna treatment for non‐dialysis patients
di: Atsushi Ohkubo, et al.
Pubblicazione: (2025)

Overall Mortality and Cardiovascular Mortality Associated With MAFLD +/ NAFLD− Versus MAFLD− / NAFLD +: A Secondary Analysis
di: Guiying Gao, et al.
Pubblicazione: (2024)

Dawn of an era of effective treatments for MAFLD
di: Cameron Gofton, et al.
Pubblicazione: (2024)

Bringing evidence to the MAFLD‐MASLD debate
di: Ziyan Pan, et al.
Pubblicazione: (2024)

Dual‐aetiology MAFLD and metabolic dysfunction
di: Ziyan Pan, et al.
Pubblicazione: (2024)

Unexplained pulmonary hypertension in peritoneal dialysis and hemodialysis patients
di: H. Nasri
Pubblicazione: (2013)

Hypokalemia results of treatment for patients in peritoneal dialysis with spironolactone
di: César A. Restrepo Valencia
Pubblicazione: (2015)

Teclistamab for relapsed refractory multiple myeloma patients on dialysis
di: P. Lebreton, et al.
Pubblicazione: (2024)

Unexplained pulmonary hypertension in peritoneal dialysis and hemodialysis patients
di: J. Etemadi
Pubblicazione: (2012)

RETRACTED: Effect of two different peritoneal dialysis modalities on wound infection in peritoneal dialysis patients: A meta‐analysis
di: Li Tang, et al.
Pubblicazione: (2024)

CHIP calls for CKD datasets
di: Vlasschaert, Caitlyn, et al.
Pubblicazione: (2025)

Dietary management of CKD in cats
Pubblicazione: (2025)

Contribution of anxiety and dialysis factors to the event of fatigue in hemodialysis patient
di: Yanti Cahyati
Pubblicazione: (2022)

Comment on “Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients”
di: Gang Zhao, et al.
Pubblicazione: (2024)

Nutrient intake in adult haemodialysis patients and influence of dialysis treatment day and patient age
di: Shatha S. Hammad, et al.
Pubblicazione: (2025)

Healthcare costs of managing MAFLD are mostly driven by hospitalisation and advanced fibrosis: cost‐analysis from a tertiary‐care, multi‐disciplinary MAFLD clinic
di: Natalie Ngu, et al.
Pubblicazione: (2026)

Reply to: Comments on “Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients”
di: Mi Na Kim, et al.
Pubblicazione: (2024)

Post‐COVID‐19 inflammation and sarcopenia in obese diabetic dialysis patients
di: Carlos Alexandre Ferreira de Oliveira, et al.
Pubblicazione: (2024)

RotaWire™ entrapment in distal right coronary artery in dialysis patient
di: Yoji Watanabe, et al.
Pubblicazione: (2024)

Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence
di: Wenqi Dong, et al.
Pubblicazione: (2025)

UDFF and Auto‐ pSWE as Promising Noninvasive Biomarkers for MAFLD
di: Jiawei Cao, et al.
Pubblicazione: (2025)

Impact of compliance with salt management guidelines before dialysis introduction on peritoneal dialysis technique survival: The importance of pre‐dialysis care and education
di: Ryu Kobayashi, et al.
Pubblicazione: (2024)

Models incorporating physical, laboratory and gut metabolite markers can be used to predict severe hepatic steatosis in MAFLD patients
di: Yi‐Hsuan Lin, et al.
Pubblicazione: (2024)

Poverty: The Common Denominator of CKD’s Global Threat
di: Guillermo García-García
Pubblicazione: (2014)

Renal clinical pharmacy services and outcomes for patients on dialysis: a scoping review
di: Rebecca Livori, et al.
Pubblicazione: (2025)

Using the concept of food as medicine to mitigate inflammation in patients undergoing peritoneal dialysis
di: Livia Alvarenga, et al.
Pubblicazione: (2024)

Impact of convective clearance on intra‐dialytic potassium removal in chronic dialysis patients
di: David A. Jaques, et al.
Pubblicazione: (2024)

Icodextrin‐induced acute generalized exanthematous pustulosis in a patient with peritoneal dialysis
di: Chun‐Hao Liu, et al.
Pubblicazione: (2024)

Autopsy findings in a rare case of pleomorphic carcinoma in a patient on dialysis
di: Keiichiro Okada, et al.
Pubblicazione: (2024)

The missing piece: A reader's view on MAFLD, diabetes, and matrix remodeling
di: Wen Qiang Xie, et al.
Pubblicazione: (2025)

The MAFLD‐MASLD debate: Does cardiovascular risk prediction define the winner?
di: Stefano Ciardullo
Pubblicazione: (2024)

Catheter meaning for the adolescents in dialysis
di: LILIANA CRISTINA MORALES
Pubblicazione: (2009)

Omics Studies in CKD: Diagnostic Opportunities and Therapeutic Potential
di: Merita Rroji, et al.
Pubblicazione: (2024)

Hypocalcemia‐induced seizures in a peritoneal dialysis (PD) patient: A case report
di: Mohammed Taha, et al.
Pubblicazione: (2024)

Microsurgical reconstruction for head and neck in patients with end‐stage renal disease undergoing dialysis
di: Chen‐Ting Hung, et al.
Pubblicazione: (2024)

Differences in hospitalization due to infectious causes between patients with hemodialysis and those with peritoneal dialysis
di: Diego Fernando Moreno-Prieto
Pubblicazione: (2020)

Development and validation of prediction model for technique failure in peritoneal dialysis patients: An observational study
di: Yue Ling, et al.
Pubblicazione: (2024)

Mechanism exploration of Wang's empirical formula on hepatoprotection in MAFLD via metabolomics and microbiomics
di: Dai, kangfu
Pubblicazione: (2025)

Redefining Obesity Improves the Identification of Advanced Fibrosis Among MAFLD / MASLD Patients
di: Alaa M. Mostafa, et al.
Pubblicazione: (2026)

Clinical outcomes of MAFLD versus NAFLD: A meta‐analysis of observational studies
di: Grazia Pennisi, et al.
Pubblicazione: (2024)